What the Oura and UC San Diego Health GLP-1 Study Will Measure, and What Your Wearable Can Show You Now

If you started a GLP-1 medication and you already wear a ring or a watch, you have probably wondered whether all that sleep and heart rate data means anything for your journey. It is a fair question, and it is one researchers are now setting out to study. No results exist yet: the trial is not yet recruiting. What does exist is a public trial registration that tells us exactly what the study plans to look at, and that is worth reading closely before you decide what to do with your own numbers.

The study, in plain terms

The trial is called SMART-BMI, and it is registered as NCT07736729. The registry lists the University of California, San Diego as sponsor, with Oura Health OY as a collaborator. Its status in the registry is "not yet recruiting", with an estimated start date of August 17, 2026.

The question it asks is narrower than the headlines might suggest. The trial investigates whether continuous wearable biometric monitoring improves weight loss and metabolic health in adults receiving obesity treatment. Participants wear an Oura Ring (Generation 4) to track sleep, heart rate and activity data.

The most interesting line in the registration is about what has not worked before. The registry states that "Prior trials that supplied wearable devices without integrating the resulting data into clinical decision-making have generally not improved weight outcomes." So this study is not really testing the ring. It tests whether care teams acting on continuous biometric data achieve better results than standard care.

Who is in it

The trial plans to enroll adults aged 18 to 64 with a BMI of 27 kg/m2 or higher who are scheduled for bariatric surgery or initiating GLP-1 therapy at UC San Diego Health. Participants need smartphone access and English or Spanish proficiency. The registry gives an estimated enrollment of 260 participants. The registry entry does not name specific GLP-1 medications, so this article does not either.

How the study is designed

The design has two phases. In Phase 1, a single-arm feasibility phase, everyone wears the Oura Ring while receiving standard obesity treatment, and clinical teams can access the biometric data during routine care. Phase 2 is a 1:1 randomized controlled trial, activated only if Phase 1 shows adequate feasibility and promising signals.

In Phase 2, both arms receive standardized health coaching; the intervention arm's care team accesses wearable data, while the control arm receives coaching without biometric access. That detail matters: the comparison is coaching with the data against coaching without it, not ring against no ring.

What it will measure

The primary outcome is percent total body weight loss at 52 weeks. The secondary outcomes are HbA1c, blood pressure, lipid profile, quality of life (PROMIS-29) and treatment persistence. The registry says Phase 1 and Phase 2 combined run through February 2031, so any answer is years away.

Treatment persistence being on that list is quietly significant. A study that counts it alongside weight and blood markers is asking a more human question than "did the number go down".

What your wearable can show you now

Until there are results, it helps to be honest about what your device is and is not. The ring in this study is used to track sleep, heart rate and activity. Those are signals about how you are living, not a verdict on whether your medication is working. We also wrote separately about protecting muscle while you lose weight and about the body signals no tracker can measure.

Here is a way to use your data that borrows the study's central idea, that data helps most when it reaches the people making decisions with you:

• Pick a few signals, not all of them. Sleep, resting heart rate and daily activity are a place to start.
• Write down context. A note on the day of a dose, a rough night or a heavy meal turns a chart into a story you can explain.
• Bring trends to your appointment, not single days. Ask your clinician which changes they would want to hear about, and how they would like to see them.
• Leave medication decisions to that conversation. A dip in sleep or a jump in heart rate is a reason to talk, never a reason to change your dose on your own.

If you are not sure where to begin with routines, our habit readiness assessment can help you see which small changes feel doable right now.

Key Takeaways

• The Oura and UC San Diego trial, NCT07736729, has no results yet; its registry status is not yet recruiting.
• It tests whether care teams acting on continuous biometric data achieve better results than standard care, not whether wearing a ring alone helps.
• The primary outcome is percent total body weight loss at 52 weeks; secondary outcomes include HbA1c, blood pressure, lipids, quality of life and treatment persistence.
• Your own sleep, heart rate and activity data is most useful as context you share with your clinician, not as a score you judge yourself by.

Keep what the medication starts

Editor: Sezen Soykut